Anti-Viral Drug Therapy Market In-deep Analysis, Experts Review Report and Advancement Outlook 2030

Anti-Viral Drug Therapy Global Market Report 2020-30: Covid 19 Implications And Growth Including: 1) By Drug Class: DNA Polymerase Inhibitors; Reverse Transcriptase Inhibitors; Protease Inhibitors; Neuraminidase Inhibitors; Others; 2) By Application: HIV; Hepatitis; Herpes; Influenza; Others Covering: AbbVie Inc.; Bristol-Myers-Squibb; Cipla; F. Hoffmann-La Roche Ltd; Gilead Sciences Inc

The demand for anti-viral drugs is anticipated to grow at a rapid pace due to the novel coronavirus outbreak. As there are no vaccines and potential treatments for Covid-19, companies are trying to repurpose existing drugs in the fight against the novel coronavirus. The use of certain existing anti-viral drugs for the covid-19 treatment is contributing to the growth of anti-viral drugs market. However, if any of these drugs under trails show further promising results in treating the coronavirus infection, the anti-viral market will see further growth.

(Special Offer: available flat 30% discount for a limited time only):
Click the link to Get a Free Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/05072013907/anti-viral-drug-therapy-global-market-report-2020-30-covid-19-implications-and-growth-including-1-by-drug-class-dna-polymerase-inhibitors-reverse-transcriptase-inhibitors-protease-inhibitors-neuraminidase-inhibitors-others-2-by-application-hiv-hepatitis-h/inquiry?source=revcitysports&Mode=54

Major players in the anti-viral drug therapy market are AbbVie Inc., Bristol-Myers-Squibb, Cipla, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Dr. Reddys Laboratories Ltd, and AstraZeneca plc.

The global anti-viral drug therapy market is expected to grow from $52.2 billion in 2019 to about $59.9 billion in 2020 as there is a surge in demand for antiretroviral drugs used in the treatment of Covid-19 patients. The market is expected to stabilize and reach $62.6 billion at a CAGR of 4.6% through 2023.

Avail Discount at :

https://www.marketinsightsreports.com/reports/05072013907/anti-viral-drug-therapy-global-market-report-2020-30-covid-19-implications-and-growth-including-1-by-drug-class-dna-polymerase-inhibitors-reverse-transcriptase-inhibitors-protease-inhibitors-neuraminidase-inhibitors-others-2-by-application-hiv-hepatitis-h/discount?source=revcitysports&mode=54

The anti-viral drug therapy market covered in this report is segmented by drug class into DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, others and by application into HIV, hepatitis, herpes, influenza, others.

In February 2020, GeoVax, a US-based pharmaceutical company, and BravoVax, a China-based pharmaceutical company, have announced plans to develop a coronavirus cure in the form of vaccine based on the formers MVA-VLP vaccine platform. BravoVax will be responsible for testing and manufacturing the vaccine as well as coordinating with the public health and regulatory authorities in China. GeoVaxs Modified Vaccinia Ankara platform enables enhanced expression and stable transgenes during the manufacturing process. Combined with immunogenicity of Virus Like Particles (VLPs), the technology enables the production of vaccines. The collaboration between these two companies is to develop a coronavirus vaccine.

Increasing public-private funding for life science research globally is expected to drive the growth of anti-viral drug therapy market . Currently, there are no drugs or vaccines approved for treatment of Covid-19 disease, however, there are several vaccines and drugs in pipeline, and are yet to be approved or launched. Governments around the world announced new grant funds for researchers in vaccines, treatment and diagnostics. Canada government announced C$275M for coronavirus research. Wellcome and the Gates Foundation announced they are joining forces with the credit card company MasterCard in a $125 million push to speed up development of drugs for treating COVID-19 infections. Hence increasing public-private funding for life science research will enhance the research and development which drive the growth of covid-19 anti-viral drug therapy market.

Companies in the anti-viral drug therapy market are continuously innovating through technological advancements to develop drugs to treat different viral infections. Biopharmaceutical companies are developing vaccines for the treatment of novel coronavirus. Technological advances in the pharmaceutical sector include development of nucleic acid vaccines that are DNA- and RNA-based, and which enable the human body to produce vaccine antigen. Applied DNA Sciences subsidiary LineaRx and Takis Biotech formed a joint venture to develop a linear DNA vaccine as a treatment for coronavirus. The JV will use Polymerase Chain Reaction (PCR)-based DNA manufacturing technology to develop the vaccine. Such initiatives and activities are projected to support market growth to a significant extent.

The emergence of alternative therapies such as naturopathy and homeopathy for the treatment of viral infections is negatively affecting the market. The development of covid-19 anti-viral drugs involves high R&D costs. The development of covid-19 anti-viral drugs involves high operating costs and requires a greater capital investment. Due to high R&D costs involved in drug development, there is growth in the demand for alternative medicines such as naturopathy and homeopathy. Saikosaponins (A, B2, C, and D), which are naturally occurring triterpene glycosides isolated from medicinal plants such as Bupleurum spp., Heteromorpha spp., and Scrophularia scorodonia, exert antiviral activity against HCoV-22E9. Saikosaponins inhibits viral attachment and penetration stages. The marketed drugs would be priced much higher than the actual manufacturing costs. Hence using this naturopathy and homeopathy medicines can restrain the market growth.

Browse the report description and TOC:

https://www.marketinsightsreports.com/reports/05072013907/anti-viral-drug-therapy-global-market-report-2020-30-covid-19-implications-and-growth-including-1-by-drug-class-dna-polymerase-inhibitors-reverse-transcriptase-inhibitors-protease-inhibitors-neuraminidase-inhibitors-others-2-by-application-hiv-hepatitis-h?source=revcitysports&Mode=54

What are the market factors that are explained in the report?

-Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

-Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

-Analytical Tools: The Global Anti-Viral Drug Therapy Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter's five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Customization of the Report: This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.

Contact Us:

IrfanTamboli (Head of Sales) - Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.